Asthma increases the risk of poor outcomes in pregnancy. Biologic treatments, such as omalizumab, may be safe during pregnancy but require shared decision-making between the patient and physician. Studies show that biologics like omalizumab do not negatively impact live births, gestational age, or congenital abnormalities. Patients with asthma, especially those with exacerbations, have higher risks of complications during pregnancy. Other biologics like dupilumab, mepolizumab, and benralizumab have also shown acceptable outcomes during pregnancy. Physicians should discuss the risks and benefits of using biologics for asthma during pregnancy with all female patients of childbearing age. Informed decisions and shared decision-making are essential in this regard.
Source link
Biologics considered safe for asthma during pregnancy
